VCYT - ベラサイト (Veracyte Inc.)

VCYTのニュース

   Veracyte says new data shows immune-checkpoint inhibitor likely to benefit i  2022/05/31 20:47:35 Seeking Alpha
Veracyte (VCYT) said on Tuesday that new data published in The Lancet Oncology suggested that its Immunoscore Immune Checkpoint assay may identify patients with metastatic…
   Veracyte to Present at Upcoming Investor Conferences  2022/05/26 12:15:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Veracyte will present at the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, and will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13. Event: William Blair 42nd Annual Growt
   Veracyte to Present at Upcoming Investor Conferences  2022/05/26 12:15:00 Kwhen Finance
   Veracyte Inc. Is A Buy Small Cap Stock: Analysts  2022/05/18 12:30:00 Marketing Sentinel
Veracyte Inc. (NASDAQ:VCYT) has a beta value of 1.18 and has seen 1.16 million shares traded in the last trading session. The company, currently valued at $1.13B, closed the last trade at $17.41 per share which meant it gained $0.83 on the day or 5.01% during that session. The VCYT stock price is -210.91% off … Veracyte Inc. Is A Buy Small Cap Stock: Analysts Read More »
   Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment  2022/05/16 20:17:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening criteria. The findings were presented today at the American Thoracic Society 2022 International Confer
   Veracyte announces key leadership promotions to advance strategic global vision  2022/01/06 13:36:53 Seeking Alpha
Veracyte (VCYT) announces key leadership promotions that further position the company to achieve its strategic global vision.Effective immediately, Tina Nova, Ph.D., is President
   Veracyte (NASDAQ:VCYT) Stock Price Up 3.4%  2021/12/24 10:06:44 Dakota Financial News
Veracyte, Inc. (NASDAQ:VCYT) rose 3.4% on Wednesday . The company traded as high as $45.14 and last traded at $44.79. Approximately 6,255 shares were traded during trading, a decline of 99% from the average daily volume of 757,466 shares. The stock had previously closed at $43.30. VCYT has been the subject of a number of []
   Karin Eastham Sells 5,000 Shares of Veracyte, Inc. (NASDAQ:VCYT) Stock  2021/12/22 09:28:45 Dakota Financial News
Veracyte, Inc. (NASDAQ:VCYT) Director Karin Eastham sold 5,000 shares of Veracyte stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed []
   Veracyte Inc. (NASDAQ: VCYT) -8.71% Decline Turns Investors Off From Company Stock  2021/12/21 16:00:00 Stocks Register
Veracyte Inc. (NASDAQ:VCYT) traded at $41.07 at close of the session on Monday, 12/20/21, made a downward move of -8.71% on its previous days price. Looking at the stock we see that its previous close was $44.99 and the beta (5Y monthly) reads 0.77 with the days price range being $40.85 $43.825. In terms Veracyte Inc. (NASDAQ: VCYT) -8.71% Decline Turns Investors Off From Company Stock Read More »
   Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis  2021/12/14 21:05:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
   Veracyte (NASDAQ:VCYT) Issues Quarterly Earnings Results  2021/11/10 17:28:41 Dakota Financial News
Veracyte (NASDAQ:VCYT) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by ($0.06), MarketWatch Earnings reports. Veracyte had a negative return on equity of 4.05% and a negative net margin of 40.06%. During the same period in the prior year, []
   Veracyte, Inc. (VCYT) CEO Marc Stapley on Q3 2021 Results - Earnings Call Transcript  2021/11/10 04:23:02 Seeking Alpha
   Veracyte EPS misses by $0.03, beats on revenue  2021/11/09 21:26:41 Seeking Alpha
   Veracyte Announces Third Quarter 2021 Financial Results  2021/11/09 21:05:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Third Quarter 2021 Financial Results

calendar